Biotech company Mitra Biotech has recently announced an agreement with Gotect Diagnostic for the exclusive right to represent Mitra in Israel.

Mitra is headquartered in Greater Boston and maintains a significant research and laboratory presence in Bengaluru, India

Mitra's CANscript™ platform recreates a patient's own tumor microenvironment in vitro, measures multiple parameters to determine whether a tumor is responding to physician-selected treatments, and then converts these parameters into a single score that predicts clinical response to each of the physician-selected therapies.

CANscript delivers powerful, individualized treatment response predictions. The company has been validated using thousands of cancer cases, with a published 90% overall correlation1 between the platform's treatment predictions and actual clinical outcomes.

Gotect is based in Tel Aviv, and supports technological and scientific innovation in the pursuit of improving patient health in Israelas well as other Mediterranean markets.

Mallik Sundaram, Mitra CEO and Co-Founder said, "We're proud and pleased to have secured a quality partner like Gotect to introduce CANscript into Israel. Together we look forward to helping inform the selection of effective treatments for Israeli cancer patients."